KetoLipix Therapeutics

KetoLipix is a preclinical-stage biotechnology company developing a new class of small molecule therapeutics designed to mimic the metabolic and neuroprotective effects of the ketogenic diet. Spun out from the Icahn School of Medicine at Mount Sinai, the company's lead programs target age-related neurodegenerative conditions such as Alzheimer's and Parkinson's disease. By activating specific metabolic pathways associated with ketone body signaling, KetoLipix aims to treat diseases characterized by mitochondrial dysfunction and neuroinflammation without requiring patients to follow a restrictive diet. The company's platform identifies compounds that induce the expression of genes typically activated during ketosis, offering a potential disease-modifying approach for various neurological and metabolic disorders.